Candriam S.C.A. Buys New Stake in Autolus Therapeutics plc (NASDAQ:AUTL)

Candriam S.C.A. acquired a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,191,401 shares of the company's stock, valued at approximately $7,500,000. Candriam S.C.A. owned approximately 1.20% of Autolus Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of AUTL. Wellington Management Group LLP increased its stake in shares of Autolus Therapeutics by 35.4% during the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock worth $87,919,000 after purchasing an additional 6,330,392 shares in the last quarter. FMR LLC grew its stake in Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company's stock worth $64,519,000 after acquiring an additional 5,478,706 shares during the period. JPMorgan Chase & Co. grew its stake in Autolus Therapeutics by 145.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock worth $4,663,000 after acquiring an additional 761,008 shares during the period. GSA Capital Partners LLP purchased a new stake in Autolus Therapeutics in the 3rd quarter worth approximately $1,082,000. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in Autolus Therapeutics in the 4th quarter worth approximately $611,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on AUTL shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, January 13th. Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price for the company in a research note on Friday, November 15th. Finally, The Goldman Sachs Group raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $10.40.

Remove Ads

Autolus Therapeutics Stock Performance

Shares of AUTL remained flat at $1.94 during mid-day trading on Tuesday. 1,050,323 shares of the company's stock were exchanged, compared to its average volume of 1,380,899. The firm has a market capitalization of $516.22 million, a PE ratio of -1.60 and a beta of 2.07. The company's fifty day simple moving average is $2.13 and its two-hundred day simple moving average is $3.03. Autolus Therapeutics plc has a 52 week low of $1.68 and a 52 week high of $6.63.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.